Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

A method is provided for reducing the severity and/or frequency of symptoms or clinical manifestations resulting from gluten ingestion by administering to a seropositive patient with symptomatic celiac disease, gluten intolerance, or gluten sensitivity latiglutenase (ALV003) in an amount from about 100 mg to about 1200 mg per day.

Oral administration of ALV003 can protect celiac disease patients and patients otherwise suffering from gluten-intolerance from the harmful effects of ingesting food containing gluten.

The present disclosure provides CAPN5 substrates and CAPN5 inhibitors, nucleic acids encoding CAPN5 substrates or CAPN5 inhibitors, methods to deliver CAPN5 substrate or CAPN5 inhibitor agents to the eye, and methods of identifying inhibitors of CAPN5.

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

The invention relates to methods of eliciting an immune response to group A streptococcal bacteria in a mammal, the method including the step of administering to the mammal an effective amount of a composition comprising an isolated p145 peptide of SEQ ID NO: 56 and/or a p145 peptide variant having an amino acid sequence at least 90% identical to SEQ ID NO: 56, and an isolated SpyCEP peptide of SEQ ID NO: 18 and/or a SpyCEP peptide variant having an amino acid sequence at least 90% identical to SEQ ID NO: 18.

The present disclosure provides CAPN5 substrates and CAPN5 inhibitors, nucleic acids encoding CAPN5 substrates or CAPN5 inhibitors, methods to deliver CAPN5 substrate or CAPN5 inhibitor agents to the eye, and methods of identifying inhibitors of CAPN5.

Polypeptides, viruses, methods and compositions provided herein are useful for the selective elimination of senescent cells. Method aspects include methods for inducing apoptosis in a senescent cell comprising administering to the cell a polynucleotide, virus, host cell, or pharmaceutical composition described herein. Other methods include expressing a pro-apoptotic gene in a senescent cell comprising administering to the cell the polynucleotide, virus, or pharmaceutical composition as described herein.

The present invention encompasses vaccines or compositions comprising the chimeric KSAC protein that possesses immunogenic and protective properties, and methods of use including administering to an animal the antigenic KSAC protein thereof to protect animals. The invention also encompasses methods for making and producing the soluble, disaggregated, refolded or active proteins from inclusion bodies produced from prokaryotes or eukaryotes.

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.